Effect of Radiofrequency Treatment in Plantar Fasciitis Patients

Launched by ANKARA UNIVERSITY · May 18, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment for chronic plantar fasciitis, a common condition that causes persistent heel pain. The study will test the effects of a procedure called radiofrequency treatment, which uses heat to help relieve pain, on patients' satisfaction, pain levels, and ability to function in daily life. Participants will receive this treatment near the back of the ankle or the heel area, guided by ultrasound to ensure accuracy.

To join the trial, participants need to be adults aged 18 to 65 who have been experiencing heel pain for at least six months and have not found relief from other treatments. They should also have significant pain, rated at a level of 4 or higher on a pain scale. However, individuals with certain health conditions, recent injuries, or those who have had similar treatments in the past may not be eligible. If you decide to participate, you can expect to receive a safe and monitored treatment designed to improve your pain and overall foot function.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18-65 years old,
• • Heel pain for at least 6 months and a diagnosis of plantar fasciitis confirmed by direct radiography and physical examination,
• • Visual analog scale is 4 or more
• • No response to conservative treatment (medical and physical medicine modalities)
• Exclusion Criteria:
• • History of trauma or calcaneus fracture,
• • Osteoarthritis, Diabetes mellitus, chronic heart disease
• • Presence of pregnancy,
• • Pain due to peripheral neuropathy or ischemia
• • Inability to tolerate injections in the heel area,
• • Allergy to local anesthetics or steroids,
• • Presence of an open wound on the side of the foot that the injection will be performed
• • Local or systemic infection at the time of the procedure
• • Previous steroid injection, radiofrequency application or ESWT (electroshock wave) treatment into the heel
• • History of surgical intervention to the heel
• • Presence of any functional limitation in the affected foot
• • Presence of neurological, hepatic and/or metabolic diseases; dermatological infections, seronegative spondyloarthropathy, bleeding diathesis
• • Failure to discontinue anticoagulant or antiaggregant within the specified periods
• • Absence of follow-up throughout the study.

Trial Officials